The headline reads as positive (94% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › MD
Pediatrix Medical Group, Inc. (MD) stock analysis
BUY 49% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Pediatrix Medical Group, Inc. (MD) BUY with 49% confidence at a price of $29.21. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$29.21
Technical picture
The 14-day RSI is 73, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.4x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $27.94 and the swing low is $22.60; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 0.24, which looks cheap relative to its expected growth.
The company reports a profit margin of 9.0% and revenue growth of +4.0%.
In its latest quarter it earned $0.72 per share, which beat the $0.65 analysts expected, with revenue +4.0% year over year.
Wall Street's average rating is 2.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "hold", with an average price target of $26.33.
Trade plan from the model
The model's long / bullish plan uses an entry near $29.21, a target of $32.54 (+11.4%) and a stop-loss at $27.42 (-6.1%).
That is a reward-to-risk ratio of about 1.9 to 1: the potential gain is larger than the potential loss.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$29.21
Target$32.54
Stop-loss$27.42
Reassess byNov 19, 2026
Research notes
MD refers to Pediatrix Medical Group. The bull case is an earnings and capital-allocation recovery: Q3 revenue rose 1.7%, adjusted EPS of $0.72 beat estimates, acquisitions and modest same-unit growth supported results, and the company has repurchased roughly 10 million shares since August 2025. The bear case is that revenue growth remains weak, salary pressure and restructuring could weigh on margins, and the stock’s recent rally has pushed it above the $26.60 consensus target and a $26.33 modeled fair value. The major catalyst today was the Q3 earnings beat, which drove MD to a new 52-week high near $30.55, though management’s cautious fourth-quarter outlook and predominantly Hold analyst ratings tempered the reaction.
The model's one-paragraph read
Leans BUY — composite score +0.49 (BUY). Technicals: RSI 73.24, MACD bullish, price above SMA50. Fundamentals: PEG 0.24, margin 9.0%, revenue growth 4.0%. Financial results: YoY revenue +4.0%, last EPS surprise +10.8%. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: positive. Internet research: MD refers to **Pediatrix Medical Group**. The bull case is an earnings and capital-allocation recovery: Q3 revenue rose 1.7%, adjusted EPS of $0.72 beat estimates, acquisitions and modest same-unit growth supported results, and the company has repurchased roughly 10 million shares since August 2025. The bear case is that revenue growth remains weak, salary pressure and restructuring could weigh on margins, and the stock’s recent rally has pushed it above the $26.60 consensus target and a $26.33 modeled fair value. The major catalyst today was the Q3 earnings beat, which drove MD to a new 52-week high near $30.55, though management’s cautious fourth-quarter outlook and predominantly Hold analyst ratings tempered the reaction. Suggested levels: entry $29.21, target $32.54, stop-loss $27.42, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for MD
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 49% | $29.21 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on MD
Oct 29, 2026 · Pediatrix Beats And Lifts Its EBITDA Floor As Volumes Recover, But The Pricing Tailwind Has Run Out
- Oct 29, 2026: Pediatrix Beats And Lifts Its EBITDA Floor As Volumes Recover, But The Pricing Tailwind Has Run Out (Earnings Whispers)
- Oct 29, 2026: Pediatrix Medical Group: Q3 Earnings Snapshot (Associated Press)
- Oct 29, 2026: Pediatrix Medical Group Reports Third Quarter Results (Business Wire)
Frequently asked questions
Is MD a buy right now?
As of Oct 29, 2026, our automated model rates Pediatrix Medical Group, Inc. (MD) BUY with 49% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for MD?
The model's most recent plan targets $32.54 with a stop-loss at $27.42, from an entry near $29.21.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.